We are live on ! Find out more
LTRN icon

Lantern Pharma

37 hedge funds and large institutions have $7.12M invested in Lantern Pharma in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more call options, than puts

Call options by funds: $108K | Put options by funds: $12K

140% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 5

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

9% more funds holding

Funds holding: 34 → 37 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.67% less ownership

Funds ownership: 22.57% → 20.9% (-1.7%)

81% less capital inflows, than outflows

Capital inflows: $144K | Capital outflows: $771K

Holders
37
Holders Change
+3
Holders Change %
+8.82%
% of All Funds
0.48%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
8
Increased
12
Reduced
5
Closed
5
Calls
$108​K
Puts
$12​K
Net Calls
+$96​K
Net Calls Change
-⁠$18​K

LTRN Hedge Fund Activity: Q2 2025 in Review

37 of the 7,634 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q2 2025, worth a combined $7.12M — down 17% from $8.63M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new LTRN positions and 5 closed out — a net gain of 3 holders — while 12 added to existing stakes and 5 trimmed.

The largest buyer was XTX Topco, opening a new position worth an estimated $42.6K. The largest seller was BIOS Capital Management, cutting an estimated $445K.

  • 37 institutional investors held Lantern Pharma (LTRN) as of Q2 2025, up from 34 in Q1 2025.
  • Funds reported $7.12M of Lantern Pharma stock for Q2 2025, down 17% quarter-over-quarter.
  • 8 funds opened new Lantern Pharma positions in Q2 2025 and 5 closed out, a net change of +3 holders.
  • The largest Lantern Pharma buyer in Q2 2025 was XTX Topco, an estimated $42.6K added.
  • The largest Lantern Pharma seller in Q2 2025 was BIOS Capital Management, an estimated $445K sold.

Based on aggregated 13F filings for Q2 2025.